ESR1 and breast cancer: Moreover, mutational disruption of ERα ligand-binding domain (which frequently occurs in therapy-resistant ER+ breast cancers patients) promoted the acquisition of a stem-cell-like phenotype and the upregulation of the Notch4 signaling pathway.